News Overview

Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to market Colestipol hydrochloride tablets.

On 23 March 2022

ISMT announced that the company has remitted the full and final settlement amount, towards the outstanding debt of the Company, to the respective Lenders/ Authorized Dealers. Powered by Capital Market – Live News

With effect from 12 March 2022

Equity indices traded higher with decent gains in early trade. The Nifty traded near the 16,700 mark. Banking and financial stocks saw buying demand while auto and FMCG shares came under selling pressure. At 9:20 IST, the barometer index, the S&P BSE Sensex, rose 169.62 points or 0.31% at 55,719.15. The Nifty 50 index gained 41.65 points or 0.25% at 16,672.90. In the broader market, […]

Indias industrial production index rose 1.3 percent year-on-year in January, preliminary data from the statistics ministry showed Friday. In the same month last year, output shrank 0.6 percent. The December growth was revised to 0.7 percent from 0.4 percent. In January, manufacturing grew 1.1 percent year-on-year, mining production rose 2.8 percent and electricity output increased 0.9 percent. In the April to January period, industrial production […]

Lupin said that it has received approval from the United States Food and Drug Administration (FDA) for Vigabatrin for oral solution USP.

In case, the Board decides to consider and declare the 2nd interim dividend, the record date for payment of Dividend would be March 29, 2022.

Zydus Lifesciences has received final approval from the USFDA to market Colestipol Hydrochloride Tablets in the strength of 1mg (US RLD: Colestid). Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Colestipol Hydrochloride is a highly complex macro molecule drug substance […]

Through this MoU, BSE and Onsurity will plan and undertake seminars, public relations events, press releases, testimonials, demonstrations.